Sexual Dysfunction in Drug-Naive or Drug-Free Male Patients with Psychosis: Prevalence and Risk Factors

BackgroundSexual dysfunction is a common symptom in patients with schizophrenia, especially in chronically medicated patients. However, the relationship between sexual dysfunction and emotional response to sexual arousal in male patients with schizophrenia remains unclear. This study aimed to assess the incidence, risk factors of sexual dysfunction in males, and their clinical correlations to sexual arousal in male patients with schizophrenia in China.MethodsA total of 162 male patients, aged 18–50 years, with schizophrenia were recruited from a psychiatric hospital in Ganzhou. The clinical symptoms were assessed by the Positive and Negative Syndrome Scale (PANSS). The Arizona Sexual Experience Scale was utilized to evaluate sexual dysfunction. Erotic images were selected from International Affective Picture System (IAPS). Sixty-eight out of the 162 subjects completed the erotic pictures reactivity task.ResultsOverall, 48 (29.6%) patients were measured as having global sexual dysfunction, 72 (44.4%) patients as having strength of sex drive dysfunction, 51 (31.5%) patients as having sexual arousal dysfunction, 55 (34.0%) patients as having penile erection dysfunction, 60 (37.0%) patients as having reached orgasm dysfunction, and 60 (37.0%) patients as having satisfaction with orgasm dysfunction. The sexual dysfunction patients had significantly higher scores on the negative symptoms of the PANSS. The only important predictor of sexual dysfunction was the severity of PANSS negative factor. The sense of pleasure and arousal post viewing erotic images in the sexual dysfunction group were lower compared to the non-sexual dysfunction group. The sense of pleasure and approach motivation were significantly negatively correlated with the severity of sexual dysfunction.ConclusionsThis study shows that nearly one-third of young and middle-aged chronically medicated male inpatients with schizophrenia suffer from sexual dysfunction. The negative factor of the PANSS can be regarded as the risk factor of sexual dysfunction. Schizophrenia patients with sexual dysfunction experienced lower pleasure and higher avoidance motivation than non-sexual dysfunction patients when exposed to erotic stimuli.

Download Full-text

Risk factors and the prognosis of sexual dysfunction in male patients with pituitary adenomas: a multivariate analysis

Asian Journal of Andrology ◽

10.4103/aja.aja_18_17 ◽

2018 ◽

Vol 20 (1) ◽

pp. 43 ◽

Cited By ~ 2

Author(s):

Wang Jia ◽

Wen-Jian-Long Zhou ◽

Shun-Chang Ma ◽

Min Zhao ◽

Chang Liu ◽

...

Keyword(s):

Risk Factors ◽

Multivariate Analysis ◽

Sexual Dysfunction ◽

Pituitary Adenomas ◽

Male Patients

Download Full-text

Risk Factors Associated with Primary and Secondary Reduced Libido in Male Patients with Sexual Dysfunction

Journal of Sexual Medicine ◽

10.1111/jsm.12043 ◽

2013 ◽

Vol 10 (4) ◽

pp. 1074-1089 ◽

Cited By ~ 51

Author(s):

Giovanni Corona ◽

Giulia Rastrelli ◽

Valdo Ricca ◽

Emmanuele A. Jannini ◽

Linda Vignozzi ◽

...

Keyword(s):

Risk Factors ◽

Sexual Dysfunction ◽

Factors Associated ◽

Male Patients

Download Full-text

Prolactin responses to im haloperidol in drug-naive and drug-experienced schizophrenic patients

European Psychiatry ◽

10.1017/s0924933800001814 ◽

1994 ◽

Vol 9 (2) ◽

pp. 91-94 ◽

Cited By ~ 3

Author(s):

M Markianos ◽

A Botsis ◽

J Hatzimanolis ◽

C Stefanis

Keyword(s):

Drug Treatment ◽

Clinical Response ◽

Dopamine Receptors ◽

Free State ◽

Neuroleptic Treatment ◽

Schizophrenic Patients ◽

Drug Naïve ◽

Male Patients ◽

One Year ◽

Drug Free

SummaryThe prolactin (PRL) responses to 5 mg im haloperidol were assessed in the drug-free state and after one month treatment with neuroleptics in 14 male schizophrenic patients who had never received drug treatment, and in 20 male patients who had discontinued their neuroleptic treatment for periods of two months to one year. Drug experienced patients showed lower PRL increases after acute haloperidol (mean 31.7 ng/ml) than drug-naive patients (mean responses 43.4 ng/ml). After treatment with neuroleptics in doses appropriate for the best clinical response, the baseline PRL levels were similar in the two groups, and im haloperidol did not cause any further PRL increases. The results provide evidence that after discontinuation of neuroleptics, the hypothalamic-pituitary dopamine receptors are subsensitive, and remain in that state for long periods of time.

Download Full-text

P03-207 Sexual dysfunction in a tunisian sample of drug free schizophrenic patients: A case-control-study

European Psychiatry ◽

10.1016/s0924-9338(11)73081-4 ◽

2011 ◽

Vol 26 (S2) ◽

pp. 1376-1376

Author(s):

Y. El Kissi ◽

S. Gaabout ◽

M. Laroussi ◽

M. Ayachi ◽

B. Ben Hadj Ali

Keyword(s):

Sexual Dysfunction ◽

Sexual Satisfaction ◽

Sexual Functioning ◽

Psychotic Disorders ◽

Sexual Experience ◽

Healthy Controls ◽

Schizophrenic Patients ◽

Drug Naïve ◽

And Gender ◽

Drug Free

IntroductionSexual dysfunction is reported by up to 80% of schizophrenic patients and seems to be mainly associated with antipsychotic medications.ObjectiveThis study aimed to compare sexual functioning and sexual dysfunction, as assessed by the Arizona Sexual Experience Scale, in drug naïve or drug free schizophrenic patients and in healthy controls.MethodA consecutive sample of 109 patients meeting DSM-IV criteria of schizophrenia was constituted in psychiatry department of Sousse Farhat Hached hospital (Tunisia), during a 24 months period. They were drug naïve or drug free for at least three months. 109 age and gender matched, consenting controls were recruited among blood donors attending Farhat Hached hospital during the same period. They were free from psychotic disorders as screened by MINI-Plus. Sexual functioning was assessed using the Arizona Sexual Experience Scale (ASEX) in sexually active patients (N = 84) and controls (N = 94).ResultsThere were no statistical differences in sexual dysfunction rates between schizophrenic patients (20.6%) and healthy controls (13.1%), according to usual threshold values. Also, global ASEX score was similar in schizophrenic patients (12.93 ± 4.48) as in healthy controls (12.61 ± 2.60). Besides, different ASEX item scores including sex drive, arousal, vaginal lubrification/penile erection and orgasm have not shown any differences between patients and controls. Only sexual satisfaction score was higher in schizophrenic patients than in healthy controls (2.73 ± 0.95 vs. 2.43 ± 0.77; p = 0.02).ConclusionOur results showed a low rate of sexual dysfunction in drug free schizophrenic patients without statistical differences with healthy controls. Only sexual satisfaction was lower in schizophrenic patients.

Download Full-text

Therapeutic options in male osteoporosis

Osteologie/Osteology ◽

10.1055/s-0038-1630134 ◽

2013 ◽

Vol 22 (04) ◽

pp. 271-276 ◽

Cited By ~ 1

Author(s):

P. Farahmand ◽

J. D. Ringe

Keyword(s):

Risk Factors ◽

Vitamin D ◽

Public Health Problem ◽

Male Osteoporosis ◽

Individual Risk ◽

Modes Of Action ◽

Increased Risk ◽

Study Results ◽

Long Term Treatment ◽

Male Patients

SummaryOsteoporosis in men is increasingly recognized as an important public health problem but affected patients are still under-diagnosed and -treated. As in women the diagnostic and therapeutic strategy has to be adapted to the individual case. In the practical management it is very important to detect possible causes of secondary osteoporosis, to explain the possibilities of basic therapy counteracting individual risk factors and communicate that osteoporosis is a chronic disease and adherence to a long-term treatment is crucial. In established severe osteoporosis a careful analgesic therapy is important to avoid further bone loss related to immobility. In elderly men with increased risk of falling insufficient Vitamin D supply or impaired activation of Vitamin D due to renal insufficiency must be taken into consideration. Specific medications available today for the treatment of male osteoporosis comprise among antiresorptive drugs the bis phosphonates alendronate, risedronate and zoledronic acid. Denosumab, the first biological therapy is approved for men with androgen deprivation therapy for prostate cancer. An important advantage of this potent antiresorptive drug is the increased adherence due to the comfortable application by sixmonthly subcutaneous injections. Study results from the 2-year multi-center randomized controlled ADAMO-Study will very soon allow the use of denosumab in all types of male osteoporosis. Teriparatide, the 34 N-terminal amino acid sequence of parathyroid hormone was approved for men with osteoporosis as an anabolic agent based on proven efficacy by different studies. Among drugs with other modes of action the D-hormone pro-drug alfacalcidol can be used in men alone or in combination with the advantage of pleiotropic effects on calcium absorption, parathyroids, bone and muscle. Recently also Strontium-ranelate was approved for male patients with the limitation to exclude men with clinical relevant cardiovascular risk factors. In general the possibilities to treat male osteoporosis have considerably improved during recent years. Today there is a choice of a spectrum of drugs from mild to strong potency with different modes of action on bone turnover to design strategies for individual male patients.

Download Full-text

Faculty Opinions recommendation of Risk factors for female sexual dysfunction in the general population: exploring factors associated with low sexual function and sexual distress.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1120562.576775 ◽

2008 ◽

Author(s):

Leslie Schover

Keyword(s):

Risk Factors ◽

Sexual Dysfunction ◽

General Population ◽

Sexual Function ◽

Female Sexual Dysfunction ◽

Factors Associated ◽

Sexual Distress

Download Full-text

Clinical and Biochemical Study of Hypoandrogenic Metabolic Syndrome in the Cardiovascular Risk Content of Male Patients

Materiale Plastice ◽

10.37358/mp.17.1.4804 ◽

2017 ◽

Vol 54 (1) ◽

pp. 137-140

Author(s):

Ana Minodora Grozdan ◽

Oana Paduraru ◽

Rodica Ghiuru ◽

Costinela Georgescu ◽

Letitia Duceac

Keyword(s):

Risk Factors ◽

Metabolic Syndrome ◽

Cardiovascular Risk ◽

Cardiovascular Risk Factors ◽

Biochemical Study ◽

Male Hypogonadism ◽

Male Patients

The aim of this study was to determine the incidence of hypoandrogenenic to male patients with S.Met., in the context of cardiovascular risk factors. It performed description of a correlation with diagnostic components of S.Met., and specifying an interrelated male hypogonadism with each of the major cardiovascular risk factors.

Download Full-text